Bifogade filer
Toleranzia AB presents Nomination Committee
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2024.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on June 7, 2023, consists of:
- Carl-Johan Spak, appointed by Flerie Invest AB
- Sören Christensen, appointed by S&B Christensen AB
- Lars Molinder, appointed by Nordic Tender AB
The Chairman of the Board of Directors, Ann-Charlotte Rosendahl, is the convener of the Nomination Committee.
The Nomination Committee shall, before the Annual General Meeting 2024, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, the election of auditors, the determination of fees and matters pertaining thereto.
Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting on June 19, 2024, can do so via e-mail to notice@toleranzia.com (label the e-mail with ‘Nomination Committee’) not later than April 15, 2024.
Information about the Nomination Committee’s work and the instructions to the Nomination Committee can be found on the company website under the section for Investors/Corporate governance. The Nomination Committee’s proposal will be presented in the summons to the Annual General Meeting 2024 and on the company’s web page: www.toleranzia.com.
For further information about the Nomination Committee, please contact:
Ann-Charlotte Rosendahl, Chairman of the Board of Directors, Toleranzia AB.
E-mail: ann-charlotte.rosendahl@toleranzia.com
Phone: +46 73-2096405
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.